
Addus HomeCare (ADUS) Stock Forecast & Price Target
Addus HomeCare (ADUS) Analyst Ratings
Bulls say
Addus HomeCare is well-positioned to capitalize on the potential repeal of the 80/20 Medicaid Access rule and potential uptick in M&A activity. Their focus on developing and rolling out a next-generation caregiver app and Homecare Homebase system is expected to improve data visibility and optimize patient care. The company's organic census growth in the Hospice segment remains strong, but there are risks related to potential changes in Medicaid policies and reimbursement rates, as well as integration challenges from the Gentiva acquisition. Despite these risks, the company's solid financials and potential for improved census dynamics make it a solid investment option, with a Market Outperform rating and a price target of $142.
Bears say
Addus HomeCare is facing challenges in its Personal Care and Hospice segments due to regulatory scrutiny and a trend towards elevated oversight in the post-acute sector. Additionally, recent financial results have shown weakness, with consolidated revenue falling short of consensus estimates and weather negatively impacting revenue. The company's reliance on acquisitions for growth and potential impact from Medicare moratoria on new agency enrollment also add to the negative outlook. Despite average rate improvements in Personal Care, these factors may continue to affect the company's financial performance in the near future.
This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.
Addus HomeCare (ADUS) Analyst Forecast & Price Prediction
Start investing in Addus HomeCare (ADUS)
Order type
Buy in
Order amount
Est. shares
0 shares